全文获取类型
收费全文 | 18869篇 |
免费 | 706篇 |
国内免费 | 563篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 590篇 |
妇产科学 | 87篇 |
基础医学 | 1585篇 |
口腔科学 | 54篇 |
临床医学 | 2208篇 |
内科学 | 2042篇 |
皮肤病学 | 189篇 |
神经病学 | 232篇 |
特种医学 | 1188篇 |
外科学 | 5602篇 |
综合类 | 2666篇 |
预防医学 | 696篇 |
眼科学 | 36篇 |
药学 | 1662篇 |
9篇 | |
中国医学 | 430篇 |
肿瘤学 | 827篇 |
出版年
2023年 | 162篇 |
2022年 | 374篇 |
2021年 | 527篇 |
2020年 | 513篇 |
2019年 | 467篇 |
2018年 | 489篇 |
2017年 | 545篇 |
2016年 | 471篇 |
2015年 | 565篇 |
2014年 | 1209篇 |
2013年 | 1140篇 |
2012年 | 1060篇 |
2011年 | 1070篇 |
2010年 | 897篇 |
2009年 | 1037篇 |
2008年 | 1041篇 |
2007年 | 1007篇 |
2006年 | 877篇 |
2005年 | 790篇 |
2004年 | 614篇 |
2003年 | 541篇 |
2002年 | 392篇 |
2001年 | 412篇 |
2000年 | 371篇 |
1999年 | 284篇 |
1998年 | 288篇 |
1997年 | 243篇 |
1996年 | 226篇 |
1995年 | 244篇 |
1994年 | 243篇 |
1993年 | 183篇 |
1992年 | 222篇 |
1991年 | 169篇 |
1990年 | 160篇 |
1989年 | 133篇 |
1988年 | 175篇 |
1987年 | 111篇 |
1986年 | 86篇 |
1985年 | 81篇 |
1984年 | 80篇 |
1983年 | 36篇 |
1982年 | 80篇 |
1981年 | 70篇 |
1980年 | 86篇 |
1979年 | 65篇 |
1978年 | 51篇 |
1977年 | 49篇 |
1976年 | 50篇 |
1975年 | 29篇 |
1973年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的探究口服补铁联合罗沙司他治疗尿毒症血液透析患者肾性贫血的效果及对不良反应的影响。方法选取本院2019年1月至2020年3月收治的尿毒症血液透析患者97例,根据随机分组法分为观察组(n=49)和对照组(n=48)。对照组口服补铁剂硫酸亚铁片治疗,观察组在对照组基础上加用罗沙司他胶囊治疗,比较两组血常规指标[红细胞压积(Hct)、血红蛋白(Hb)、转铁蛋白饱和度(TSAT)、血清铁蛋白(SF)]及不良反应发生率。结果治疗前,两组Hb、Hct、SF、TSAT水平比较差异无统计学意义;治疗10周后,两组Hb、Hct、SF、TSAT水平均高于治疗前,且观察组高于照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论尿毒症血液透析患者口服补铁联合罗沙司治疗可改善肾性贫血病情,且安全性高,不良反应少。 相似文献
2.
3.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
4.
目的:观察肾康注射液联合青霉素与替米沙坦治疗肾小球肾炎合并急性间质性肾炎患者的效果。方法:选取134例肾小球肾炎合并急性间质性肾炎患者为研究对象,按随机数字表法将其分成观察组与对照组各67例。对照组给予青霉素联合替米沙坦治疗,观察组在对照组基础上加用肾康注射液治疗,比较两组临床疗效、治疗前后肾功能指标[血管内皮生长因子(VEGF)、胱抑素C(CysC)、单核细胞趋化蛋白-1(MCP-1)]水平和不良反应发生率。结果:观察组治疗总有效率为97.01%(65/67),明显高于对照组的85.07%(57/67),差异有统计学意义(P<0.05);治疗后,观察组VEGF、CysC和MCP-1水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:肾康注射液联合青霉素与替米沙坦治疗肾小球肾炎合并急性间质性肾炎患者可提高治疗总有效率,降低肾功能指标水平,其效果优于青霉素联合替米沙坦治疗。 相似文献
5.
6.
7.
目的探讨儿童肾脏非霍奇金淋巴瘤CT平扫及增强表现,提高对该病的认识。方法回顾性分析50例经手术或活检病理证实的儿童肾脏非霍奇金淋巴瘤(原发性1例,继发性49例)CT表现。结果50例儿童肾脏非霍奇金淋巴瘤影像学表现多样,根据CT表现可分为5型:多发结节型、单发结节型、弥漫浸润型、邻近后腹膜淋巴瘤侵犯型及肾周肿块型。本组36例多发结节型,其中双侧多发34例,单侧多发2例;8例单发结节型,其中右侧单发6例,左侧单发2例;3例弥漫浸润型;2例邻近后腹膜淋巴瘤侵犯型;1例肾周肿块型。结论儿童肾脏非霍奇金淋巴瘤CT表现形式多样,但具有一定特征,对于准确诊断儿童肾脏非霍奇金淋巴瘤,指导临床分期、制定治疗方案及观察疗效具有重要意义。 相似文献
8.
9.
王涛赵淑青刘考 《中国卫生质量管理》2022,(12):089-92
目的降低终末期肾病患者动静脉内瘘成熟不良率。方法成立品管圈圈组,通过现状调查、原因解析明确问题真因,从制定动静脉内瘘院前指导规范,建立多学科协作模式;实施“VAP”评估模式,制定围手术期标准化管理流程;构建“互联网 +”智能宣教模式,优化院外延伸服务三方面进行改进。结果终末期肾病患者动静脉内瘘成熟不良率由10.6%降低至3.3%。结论开展品管圈活动降低了终末期肾病患者动静脉内瘘成熟不良率。 相似文献
10.
《Journal of vascular and interventional radiology : JVIR》2022,33(10):1143-1150
PurposeTo report the 5-year results from the Pivotal Multicenter Trial of Ultrasound-Guided Percutaneous Arteriovenous Fistula (pAVF) Creation for Hemodialysis Access.Materials and MethodsThe retrospective review of 107 intent-to-treat (ITT) patients from the pivotal trial provided a long-term follow-up population (LTP) of 85 patients with a median follow-up duration of 50 months (range, 12–60 months). Data evaluated in the LTP group were fistula maturation and usage, secondary procedures, and complications. The Kaplan-Meier analysis of primary patency, assisted primary patency, cumulative patency, and functional patency (time from 2-needle cannulation to abandonment) were performed for the ITT population.ResultsIn the LTP, 99% (84 of 85) of fistulae were mature, with 99% (78 of 79) of patients requiring hemodialysis using their pAVF. Sustained fistula use (2-needle cannulation at the prescribed rate, 2 of 3 sessions) was achieved in 92% (78 of 85) of patients, with 7 patients not using their pAVF because they were not on dialysis (n = 4), were on peritoneal dialysis (n = 2), and refused to use fistula (n = 1). Fistula maintenance was required in 31.8% (27 of 85) of patients and included fistula dysfunction (21.2%), thrombosis (5.9%), cannulation injury (12.9%), and arm swelling (4.7%). The number of procedures performed per patient per year to maintain function and patency was 0.32 (91 of 288) for years 2–5. The cumulative patency rates were 89.5%, 88.4%, 88.4%, 85.6%, and 82.0% for years 1, 2, 3, 4, and 5, respectively. The functional patency was 91.8% at the end of the study. There were no major complications related to pAVF during the long-term follow-up.ConclusionsPercutaneous fistulae have provided clinically effective and durable access for hemodialysis with low complications. The continued use and evaluation of pAVF are warranted. 相似文献